This was a very important meeting with top experts that are trying to change guidelines. This FDA panel recently recommended removing the warning (“black box”) labels on menopausal HRT, citing potential benefits like reduced heart attack and bone fracture risk—and arguing the warning discourages appropriate use.
Hopefully, we will see progress in this field after the confusing and sometimes misleading conclusions of the WHI (“Women’s Health Initiative”), a large National Institutes of Health trial...
The FDA finally held a hearing on menopause—and it was long overdue. Georgie Kovacs breaks down the powerful expert testimony, the systemic failures, and why this matters for every woman navigating midlife care.
In this grounded recap, you’ll learn:
• Why the FDA’s black box warning on vaginal estrogen may be misleading
• The difference between systemic and local hormone absorption—and why it matters
• How testosterone access for women remains limited despite clear clinical need